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Abstract
Background: Colorectal cancer and B cell chronic lymphocytic leukaemia (CLL) have a significant
incidence, which are increasing with the aging population. Evidence has been presented in the
literature to suggest that the synchronous presentation of colorectal cancer and B cell CLL may be
more than simply coincidental for these two common malignancies. We report an unusual case of
a presumed B cell CLL diagnosed on the basis of histological analysis of lymph nodes recovered
from a resection specimen for rectal adenocarcinoma. We considered aetiological factors which
may have linked the synchronous diagnosis of the two malignancies and the potential implications
for the natural history of the two malignancies on one another.
Case presentation: A 70-year-old male underwent low anterior resection with total mesorectal
excision for a rectal adenocarcinoma. His co-morbid conditions were chronic obstructive airways
disease and ischaemic heart disease. General examination revealed no lymphadenopathy. Full blood
count, urea and electrolytes and liver function tests were all within normal limits. As well as
confirming a pT3 N1 adenocarcinoma, histological analysis showed lymph nodes with an infiltrate
of small lymphoid cells. Immunohistochemical studies showed these cells to be in keeping with B
cell CLL.
Conclusion: Whilst unable to identify any common aetiological factors in the two malignancies in
our patient, immunosuppression and genetic abnormalities have been identified as possible bases
for an observed epidemiological association between colorectal cancer and haematological
malignancies. Examples such as our case of synchronous diagnosis of two malignancies in a patient
are likely to increase with the aging population. The potential affects of one malignancy on the
natural history of the other warrants further study. In our case, we considered that slow
progression of the B cell CLL may increase the risk of recurrent rectal adenocarcinoma.
Background
Colorectal cancer is the third commonest malignancy in
Europe and North America. B cell chronic lymphocytic
leukaemia (CLL) accounts for 0.8% of all cancers at any
point in time [1]. One of the complications of B cell CLL
is an associated increased risk of subsequent second
malignancies, most commonly melanoma, soft-tissue sar-
coma and colorectal and lung carcinoma [2-4]. Immuno-
suppression associated with the long term nature of B cell
CLL has been proposed as the basis of this increased risk
[5,6].
Published: 30 October 2007
World Journal of Surgical Oncology 2007, 5:126 doi:10.1186/1477-7819-5-126
Received: 23 April 2007
Accepted: 30 October 2007
This article is available from: http://www.wjso.com/content/5/1/126
© 2007 Dennis and Alberts; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.World Journal of Surgical Oncology 2007, 5:126 http://www.wjso.com/content/5/1/126
Page 2 of 4
(page number not for citation purposes)
Whilst patients with advanced B cell CLL may experience
weight loss, recurrent infections, bleeding secondary to
thrombocytopenia, and/or anaemia, 25% of patients are
asymptomatic and diagnosed on the basis of peripheral
blood markers. Asymptomatic B cell CLL, diagnosed on
peripheral blood markers or symptomatic presentation of
B cell CLL has been described synchronously with rectal
cancer [7]. We report an unusual case of a presumed B cell
CLL diagnosed on the basis of histological analysis of
lymph nodes recovered from a resection specimen for rec-
tal adenocarcinoma. We considered the diagnostic quan-
daries of coincidental findings at examination of
colorectal resection specimens; the possibility that a syn-
chronous diagnosis may reflect an aetiological link
between the malignancies in our patient; the possibility
that the natural history of either one malignancy could be
altered by the presence or treatment of the other.
Case presentation
A 70-year-old male presented with an eight month history
of looser stools. His medical history included a right lung
lobectomy for tuberculosis aged 20, chronic obstructive
airways disease and ischaemic heart disease. He was a
long-term smoker.
General examination showed him to be well with no lym-
phadenopathy. No mass was palpable on digital rectal
examination. Full blood count, urea and electrolytes and
liver function tests were all within normal limits.
Flexible sigmoidoscopy and biopsy identified a rectal ade-
nocarcinoma at 8 cm from the anal margin. MRI showed
a normal liver and no para-aortic lymphadenopathy. A
moderately bulky tumour was identifiable in the mid/low
rectum, 5 cm in length. Local staging with MRI was T2
although the tumour was noted to be very close to the
levator plate especially on the left. Perirectal and presacral
lymph nodes were seen, the largest of which was 1 cm in
short axis. CT scan of the chest did not identify any meta-
static disease.
At laparotomy no peritoneal disease, liver metastases or
abnormal lymph nodes were seen. A low anterior resec-
tion with total mesorectal excision was performed. Recov-
ery was complicated by chest sepsis and prolonged ileus
and the patient was fit for discharge on day 14 post sur-
gery.
Pathologic findings
Microscopic examination showed complete resection
margins of a moderately differentiated adenocarcinoma
extending through the muscularis propria. Metastatic ade-
nocarcinoma was also identified in one of the twenty one
lymph nodes. By UICC staging this was therefore pT3 N1
MX. There was no evidence of extramural vascular inva-
sion. Several lymph nodes showed partial effacement of
the normal lymphoid architecture by an infiltrate of small
lymphoid cells in which many pseudoproliferation cen-
tres were evident.
Immunohistochemical staining
Immunohistochemical studies confirmed the presence of
CD20 positive B lymphoid infiltrate that co-expressed
CD5, CD23 and BCL2 and was negative for cyclin D1,
CD10 and BCL6 (DakoCytomation, Ely, UK).
This overall picture was considered consistent with a low
grade B cell chronic lymphocytic leukaemia.
Discussion
The meticulous examination of lymph nodes in colorectal
resection specimens is crucial to evaluating prognosis and
planning adjuvant therapies. On rare occasions such
examinations will inevitably discover coincidental pathol-
ogies, presenting pathologists and clinicians with diag-
nostic, prognostic and therapeutic quandaries. This case
was an unusual synchronous diagnosis of a presumed
early B cell CLL and adenocarcinoma of the rectum. It pre-
sented the quandaries of the diagnosis of B cell CLL, the
possibility of a link between the two malignancies and
potential implications for the natural history of either
malignancy.
In this case the histological and immunohistochemical
findings were considered sufficient for a provisional diag-
nosis of B cell CLL. A formal diagnosis of B cell CLL could
not be made since the patient did not have a lymphocyto-
sis and a bone marrow biopsy was not considered appro-
priate at this stage of presentation. In modern medical
practice these diagnostic quandaries need to be carefully
discussed with the patient. However it is all too easy for
confusion to develop amongst the various medical staff
involved in a patient's care, the patient and their relatives.
The most likely explanation for this synchronous diagno-
sis of a presumed B cell CLL and adenocarcinoma of the
rectum is purely coincidental. However in the synchro-
nous presentation of colorectal cancer and B cell CLL an
epidemiological association has been noted which goes
further than simple coincidence [8]. This synchronous
relationship has been explained in terms of immunosup-
pression over a prolonged period due asymptomatic B cell
CLL and a subsequent development of colorectal cancer,
in fact, in a metachronous manner. This is consistent with
the observed increase in the long term risk of solid organ
malignancies in a patient diagnosed with B cell CLL [2,3],
where immunosuppression over a prolonged period has
also been postulated as the basis for the increased risk
[5,6]. Given the very early stage of the presumed B cell CLL
in our patient it would seem unlikely that immunosup-World Journal of Surgical Oncology 2007, 5:126 http://www.wjso.com/content/5/1/126
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pression has played a significant role in the development
of the primary rectal carcinoma.
An alternative explanation for the link between colorectal
cancer and B cell lymphocytic leukaemia may come from
our increasing understanding of tumour genetics. A com-
mon alteration in a locus of chromosome 7 has been sug-
gested as a genetic basis for an association between
haematological malignancy and hereditary nonpolyposis
colon cancer [9]. Leukaemia and colorectal cancer are
both associated with Li-Fraumeni syndrome and muta-
tions of the p53 gene/gene expression. Abnormalities in
the p53 gene expression have been demonstrated in 10–
15% of B cell CLL patients and 75% of colorectal carci-
noma patients. In B cell CLL p53 gene expression has been
shown to be a marker of aggressive disease with a poorer
prognosis [10]. With the exception of Li-Fraumeni syn-
drome, single gene mutations would not account for the
development of both malignancies in a single patient.
However altered p53 expression may illustrate common
pathways, many of which remain unknown, which may
increase an individual's risk of more than one form of
malignancy. As a matter of interest we performed immu-
nohistochemistry for p53 protein expression in our
patient's histopathological specimens and identified p53
expression in the cells of the adenocarcinoma, but not the
B cells of the CLL.
In the synchronous diagnosis of B cell CLL and rectal car-
cinoma, as well as implying the possibility of common
aetiological factors, we also considered whether either dis-
ease or its treatment might affect the natural history of the
other. This patient had pT3 N1 stage rectal adenocarci-
noma and a predicted 5 year survival in of 68% – 62%
[11,12]. On the basis of the N1 stage disease the patient
was offered adjuvant chemotherapy. As first line chemo-
therapy the patient received a course of 5-fluorouracil.
There is no evidence to suggest that administration of 5-
fluorouracil alters the natural history of B cell CLL.
Variability in the rate of B cell CLL disease progression and
incidence of disease related complications can make the
decision to treat a more complex one. Treatment of early
stage B cell CLL with chemotherapy does not confer any
survival advantage over conservative management. Treat-
ment of B cell CLL also does not reduce the incidence of
second neoplasia [13]. Given the very early stage of a pre-
sumed B cell CLL in our patient we decided to monitor
him until evidence of disease progression. However with
slow progression of the B cell CLL the patient may become
relatively immunosuppressed for a prolonged period
before treatment is indicated. Given the established
increased risk of primary colorectal cancer potentially
associated with this situation it is of concern that our
patient may be at increased risk of recurrent rectal carci-
noma in the future. The risk of recurrent solid organ
tumours with a diagnosis of B cell CLL has not been stud-
ied. In our case any increased risk of recurrent rectal carci-
noma would potentially alter the duration of surveillance.
Surveillance in our hospital for rectal carcinoma is 5 years
with annual CT chest and abdomen. With a predicted
median survival of >7 years with the B cell CLL surveil-
lance beyond 5 years may be prudent.
Conclusion
The meticulous examination of lymph nodes in colorectal
carcinoma can reveal other unsuspected malignancies. We
have described an unusual case of synchronous rectal ade-
nocarcinoma and a presumed early B cell CLL diagnosed
on the basis of histological examination of the rectal
resection specimen. Whilst unable to identify any com-
mon aetiological factors in the two malignancies in our
patient, immunosuppression and common tumour
genetics may form the bases for an observed epidemiolog-
ical association between colorectal cancer and haemato-
logical malignancies. Examples such as our case of
synchronous diagnosis of two malignancies in a patient
are likely to increase with the aging population. The
potential affects of one malignancy on the natural history
of the other warrants further study. In our case, we consid-
ered that slow progression of the presumed B cell CLL may
increase the risk of recurrent rectal adenocarcinoma and
prolonged surveillance may be prudent.
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